Full Press Release Details
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2026 and provided business highlights.
PRTA Neutral Sentiment
Prothena Reports Third Quarter 2026 Financial Results and Business Highlights
Key Takeaway: Prothena announced its financial results for the third quarter and the first nine months of 2026. The company also shared business highlights during this reporting period. The provided text does not disclose specific financial figures or detailed performance metrics for this quarter.
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+143%
120-day peak, hindsight
Typical move
4.8%
average across 7 past catalysts
Cash runway
~32 mo
Minimal dilution risk
Lead asset
Prasinezumab
Phase 3 · Parkinsons Disease
Frequently Asked Questions
What period does the report cover?
It covers the third quarter and the first nine months of 2026.
Did Prothena release specific financial figures?
The article text provided does not list specific financial figures or metrics.
What other updates were included?
The company also provided business highlights alongside the financial results.
Where was the announcement made?
The press release originated from Dublin, Ireland.